Journal of Experimental & Clinical Cancer Research

Table 1 Relationships between miR-141 expression and SCLC patient clinical characteristics

From: Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer

		Plasma exosomes (n = 53)			Serum (n = 69)
		miR-141 low level	miR-141 high level	P value	miR-141 low level	miR-141 high level	P value
Sex	Female	12	7	0.1248	7	7	0.9516
Sex	Male	14	20	0.1248	27	28	0.9516
Age	< 60	11	17	0.1321	12	16	0.3782
Age	≥60	15	10	0.1321	22	19	0.3782
T	T1-T2	17	8	0.0091**	17	11	0.1163
T	T3-T4	9	19	0.0091**	17	24	0.1163
N	N0-N1	12	5	0.0312*	7	3	0.1563
N	N2-N3	14	22	0.0312*	27	32	0.1563
M	M0	23	18	0.0581	25	15	0.0099**
M	M1	3	9	0.0581	9	20	0.0099**
Stage	I-II	11	5	0.0593	4	1	0.1536
Stage	III-IV	15	22	0.0593	30	34	0.1536
Stage	LD	20	12	0.0244*	21	14	0.0706
Stage	ED	6	15	0.0244*	13	21	0.0706

LD, limited disease; ED, extensive disease
miR-141 low- and high-level group were defined according to the median of miR-141 expression in the corresponding cohort of SCLC patients

Back to article page

ISSN: 1756-9966

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com